Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to lower total failure: day 28 (unadjusted) compared with artemether‐lumefantrine (AL) (low certainty).
2 findings from 1 review
Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal AST increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical improvement compared with beclometasone (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Quality of life improvement by at least 6 points · thyroid‐associated ophthalmopathy
1 finding from 1 review
Adverse events · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in adverse events compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review
Failure of PDA closure after first course of treatment (assessed by post‐treatment ECHO) · preterm infants with PDA
Paracetamol showed no clear difference in failure of PDA closure after first course of treatment (assessed by… compared with indomethacin (low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay · preterm infants with PDA
Paracetamol showed no clear difference in all‐cause mortality during initial hospital stay (by clinical… compared with indomethacin (low certainty).
1 finding from 1 review
Necrotizing enterocolitis during initial hospital stay (by radiological diagnosis) · preterm infants with PDA
Paracetamol may leads to lower necrotizing enterocolitis during initial hospital stay (by… compared with indomethacin (low certainty).
1 finding from 1 review